How Ozempic and Mounjaro Affect the Brain

✓ Medically reviewed | Published: | Evidence level: 1A
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) mimic gut hormones whose receptors also sit in brain regions that regulate hunger, nausea and reward. Researchers are now studying how these central effects may shape cravings, mood and cognition. Evidence is still emerging, and large Alzheimer's trials of semaglutide did not show a slowing of disease progression.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pharmacology

Quick Facts

Drug class
GLP-1 receptor agonists
Key brain areas
Hypothalamus and brainstem
Alzheimer's trials
Did not slow progression

How do GLP-1 drugs work in the brain?

Quick answer: GLP-1 drugs bind receptors in brain regions such as the hypothalamus and brainstem, reducing hunger signals and increasing the feeling of fullness.

Glucagon-like peptide-1 (GLP-1) is a hormone released by the gut after eating. Drugs such as semaglutide and tirzepatide (which also activates the GIP receptor) are designed to mimic it. Although they were first developed to improve blood sugar control in type 2 diabetes, much of their weight-loss effect is believed to come from actions in the central nervous system. GLP-1 receptors are found in the hypothalamus, which governs energy balance, and in the brainstem, which coordinates satiety and nausea signals.

By acting on these circuits, the drugs appear to dampen hunger and the preoccupation with food that many patients describe as 'food noise.' They also slow gastric emptying, which reinforces fullness. Researchers continue to debate how much of the effect comes from direct brain access versus signals relayed through the vagus nerve, and the exact pathways remain an active area of study.

Could GLP-1 medications change reward, mood and cognition?

Quick answer: Early research suggests GLP-1 drugs may influence reward pathways and possibly cognition, but results are mixed and the evidence is not yet conclusive.

Because GLP-1 receptors are also present in areas tied to reward processing, scientists are investigating whether these drugs affect cravings beyond food, including alcohol and other substances. Observational data and early clinical studies have prompted trials in addiction, though findings so far are preliminary. Reports of mood changes have led regulators and researchers to monitor psychiatric safety, and current evidence does not establish a clear causal link either way.

Interest in dementia prevention has also grown, partly because of links between metabolic disease and cognitive decline. However, the large phase 3 EVOKE and EVOKE+ trials of oral semaglutide in early symptomatic Alzheimer's disease, reported by Novo Nordisk, did not show slowed disease progression. This suggests any brain benefits seen in observational studies may relate to better metabolic and vascular health rather than a direct anti-Alzheimer's effect. Patients should discuss individual risks and benefits with a clinician.

Frequently Asked Questions

Research indicates they activate GLP-1 receptors in brain regions that regulate appetite, though some effects may also be relayed via the vagus nerve and gut.

Not according to current evidence. Large phase 3 trials of oral semaglutide in early Alzheimer's did not slow disease progression.

No. Do not change treatment without consulting your prescriber, who can weigh your individual benefits and risks.

References

  1. ScienceDaily. Ozempic and Mounjaro may have a surprising effect on your brain. November 2026.
  2. U.S. Food and Drug Administration. Prescribing information for Ozempic, Wegovy, Mounjaro and Zepbound.
  3. Novo Nordisk. EVOKE and EVOKE+ phase 3 trial announcements on semaglutide in early Alzheimer's disease.